Global Neurodegenerative Drugs Market Report 2021: Market to Reach $47.8 Billion by 2027 – Parkinson’s Disease Segment is Expected to Account for $15.4 Billion – ResearchAndMarkets.com

Global Neurodegenerative Drugs Market Report 2021: Market to Reach $47.8 Billion by 2027 – Parkinson’s Disease Segment is Expected to Account for $15.4 Billion – ResearchAndMarkets.com




Global Neurodegenerative Drugs Market Report 2021: Market to Reach $47.8 Billion by 2027 – Parkinson’s Disease Segment is Expected to Account for $15.4 Billion – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Neurodegenerative Drugs – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Global Neurodegenerative Drugs Market to Reach $47.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Neurodegenerative Drugs estimated at US$34.3 Billion in the year 2020, is projected to reach a revised size of US$47.8 Billion by 2027, growing at a CAGR of 4.9% over the analysis period 2020-2027.

Parkinson’s Disease, one of the segments analyzed in the report, is projected to record a 5.6% CAGR and reach US$15.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Huntington Disease segment is readjusted to a revised 4.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $9.3 Billion, While China is Forecast to Grow at 7.5% CAGR

The Neurodegenerative Drugs market in the U.S. is estimated at US$9.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$9.8 Billion by the year 2027 trailing a CAGR of 7.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 4.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR.

Amyotrophic Lateral Sclerosis Segment to Record 4.6% CAGR

In the global Amyotrophic Lateral Sclerosis segment, USA, Canada, Japan, China and Europe will drive the 4.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$5.1 Billion in the year 2020 will reach a projected size of US$6.9 Billion by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.4 Billion by the year 2027, while Latin America will expand at a 5.5% CAGR through the analysis period.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Impact of COVID-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS (Total 165 Featured):

  • Biogen, Inc.
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer, Inc.
  • Reata Pharmaceuticals, Inc.
  • Sage Therapeutics, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

  • United States
  • Canada
  • Japan
  • China
  • Europe
  • France
  • Germany
  • Italy
  • United Kingdom
  • Spain
  • Russia
  • Rest of Europe
  • Asia-Pacific
  • Australia
  • India
  • South Korea
  • Rest Of Asia-Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East
  • Iran
  • Israel
  • Saudi Arabia
  • United Arab Emirates
  • Rest of Middle East
  • Africa

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/kcbs9u

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900